Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionaldehyde SCHEMBL8906570 | 1.00 | LMNA (0.60) | LMNAALDH1A1MAPK1TDP1THRB | |
| Propionaldehyde SCHEMBL1523503 | 0.95 | LMNA (0.67) | LMNAALDH1A1MAPK1TDP1THRB | |
| Butane SCHEMBL2557609 | 0.87 | LMNA (0.63) | LMNATHRB | |
| Butane SCHEMBL818136 | 0.87 | LMNA (0.63) | LMNATHRBTSHR | |
| Butane SCHEMBL11232709 | 0.86 | LMNA (0.55) | LMNAALDH1A1THRB | |
| Butane SCHEMBL1088110 | 0.86 | LMNA (0.55) | LMNAALDH1A1THRB | |
| Butane SCHEMBL8312214 | 0.85 | LMNA (0.60) | LMNATHRB | |
| Butane SCHEMBL1866739 | 0.84 | LMNA (0.86) | LMNATHRB | |
| Butane SCHEMBL49299 | 0.84 | LMNA (0.86) | LMNATHRB | |
| Butanal SCHEMBL264581 | 0.83 | ALDH1A1 (0.57) | LMNAALDH1A1MAPK1TDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189544-A1 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS INC (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1572728-B1 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2535347-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | Mountain View Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8129330-B2 | Complex of polyoxyethylene glycol with active material | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-1572728-A2 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | Mountain View Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004030617-A2 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | LMNA 2526/4885ALDH1A1 3287/4885MAPK1 3488/4885 |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | LMNA 2526/4885ALDH1A1 3287/4885MAPK1 3488/4885 |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | CD14, HLA-C, HLA-A | LMNA 2526/4885ALDH1A1 3287/4885MAPK1 3488/4885 |
| US-20170189544-A1 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | CD14, HLA-C, HLA-A | LMNA 2526/4885ALDH1A1 3287/4885MAPK1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.